Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (4,127,970)	$ (2,813,312)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	68,310	47,550
Accretion of debt discount	920,648	0
Stock Based Compensation	84,000	317,664
Changes in assets and liabilities:
Prepaid expenses and other receivables	(397,926)	206,716
Inventory	(531,927)	(186,137)
Accounts payable	(126,910)	21,259
Liability due to related party	(434,170)	(268,483)
Other liabilities and accrued expenses	(92,819)	110,780
Net cash used in operating activities	(4,638,764)	(2,563,963)
Cash Flows from Investing Activities:
Capitalized patent costs	(48,273)	(50,570)
Software development costs in process	(446,455)	0
Purchase of property and equipment	(70,547)	(162,615)
Net cash (used in) provided by investing activities	(565,275)	(213,185)
Cash Flows from Financing Activities:
Costs incurred in relation to equity financing	(957,193)	(9,575)
Commission paid on note payable	(325,000)	0
Proceeds from issuance of notes	5,000,000	0
Proceeds from issuance of common stock in relation to equity financing	15,750,672	152,492
Proceeds from warrant exercise	394,475	26,000
Repayments of note payable	(300,000)	0
Repayment of insurance financing	(82,555)	(28,207)
Net cash provided by financing activities	19,480,399	140,710
Net increase / (decrease) in cash	14,276,360	(2,636,438)
Effect of exchange rate changes on cash	577,318	(36,563)
Cash at beginning of period	106,107	3,740,664
Cash at end of period	14,959,785	1,067,663
Supplemental disclosure of non-cash financing activities:
Gross amount of insurance funded through note payable	0	132,352
Licenses acquired through issuance of restricted common stock	$ 100,000	$ 0